Skip to content

Radiomic signatures based on pretreatment 18F-FDG PET/CT combined clinicopathological characters as early prognostic biomarkers among patients with invasive breast cancer

Radiomic signatures based on pretreatment 18F-FDG PET/CT combined clinicopathological characters as early prognostic biomarkers among patients with invasive breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070309
Enrollment
Unknown
Registered
2023-04-09
Start date
2023-04-09
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

control group:survival time
progression group:survival time

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were as follows: a. without any therapy before the standard examination of 18F-FDG PET/CT; b. diagnosed with invasive carcinoma of breast cancer confirmed by puncture biopsy or surgical specimen; c. with available clinical records and pathological data; d. with IHC examination included the results of 4 molecular receptors performance (ER, PR, HER-2 and Ki-67).

Exclusion criteria

Exclusion criteria: Exclusion criteria were as follows: a. with a suboptimal quality of 18F-FDG PET/CT images due to motion artefacts or abnormal biodistribution of tracer; b. with a too small mass size to outline ROI for measurement (short-axis diameter <1 cm); c. concomitantly with other types of tumors; d. confirmed as other specific histological type of breast cancer e. total follow-up time was less than 8 months.

Design outcomes

Primary

MeasureTime frame
progression-free survival time;

Secondary

MeasureTime frame
overall survival time;

Countries

China

Contacts

Public ContactDeng Shengming

The First Affiliated Hospital of Soochow University

dshming@163.com+86 15051510189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026